{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-031379","form_type":"8-K","ticker":"PVCT","cik":"0000315545","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2026-06-30T23:37:26+00:00","discovered_at":"2026-07-01T10:05:00.265115+00:00","generated_at":"2026-07-01T10:05:47.916639+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Provectus Biopharmaceuticals converts $542,500 in accrued director fees into Series D-1 Preferred Stock","bullets":["Board approved conversion of $542,500 in accrued directors' fees into 189,554 shares of Series D-1 Preferred Stock.","Preferred Stock is convertible into 1,895,540 shares of Common Stock.","Issuance satisfies outstanding cash fees, not under 2024 Equity Compensation Plan.","Conversion effective as of June 30, 2026, based on May 14, 2026 Board approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-031379","json":"https://secwatch.observer/filing/0001493152-26-031379.json","markdown":"https://secwatch.observer/filing/0001493152-26-031379.md","text":"https://secwatch.observer/filing/0001493152-26-031379.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/315545/000149315226031379/0001493152-26-031379-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/315545/000149315226031379/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-01T10:05:47.916639+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}